CPT-11 (irinotecan) and 5-fluorouracil: A promising combination for therapy of colorectal cancer

European Journal of Cancer Part A

Volumn 32, Issue SUPPL. 3, 1996, Pages

  Saltz, L ^a   Shimada, Y ^b   Khayat, D ^c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

5 FU; colorectal cancer; CPT 11

Indexed keywords

DNA TOPOISOMERASE INHIBITOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; ISOMERASE INHIBITOR;

CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; STOMATITIS; VOMITING;

EID: 0029907966     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(96)00294-8     Document Type: Article

References (25)

1. Rougier P, Culine S, Bugat R, et al. A phase II study of CPT-11 (irinotecan) in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with 5-FU-based chemotherapy. J Clin Oncol, in press.
2. Conti JA, Kemeny NE, Saltz LB, et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 1996, 14, 709-715.
3. Pitot HC, Wender D, O'Connell MJ, et al. A phase II trial of CPT-11 (irinotecan) in patients with metastatic colorectal carcinoma: a North Central Cancer Treatment Group (NCCTG) study. 30th Annual Meeting of the American Society of Clinical Oncology, 14-17 May 1994, Dallas, Texas (abstract 573).
4. Rothenberg ML, Eckardt JR, Burris III HA, et al. Irinotecan (CPT-11) as second line therapy for PTS with 5-FU-refractory colorectal cancer. 30th Annual Meeting of the American Society of Clinical Oncology, 14-17 May 1994, Dallas, Texas (abstract 578).
5. Shimada Y, Yashino M, Wakui A, et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 1993, 11, 909-913.
6. Armand JP, Ducreux M, Mahjoubi M, et al. CPT-11 (irinotecan) in the treatment of colorectal cancer. Eur J Cancer 1995, 31A, 1283-1287.
7. Chu E, Takimoto CH. Antimetabolites. In DeVita Jr VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 4th edition. Philadelphia, JB Lippincott, 1993, 358-374.
8. Cohen AM, Minsky BD, Schilsky RL. Colon Cancer. In DeVita Jr VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 4th edition. Philadelphia, JB Lippincott, 1993, 929-977.
9. Sasaki Y, Ohtsu A, Shimada Y, Ono K, Saijo N. Simultaneous administration of CPT-11 and SN-38 in patients with advanced colorectal cancer [correspondence]. J Natl Cancer Inst 1994, 86, 1096-1098.
10. Shimada Y. Topoisomerase I inhibitor: combination chemotherapy with CPT-11 in gastrointestinal cancers. 2nd International Conference on Biology, Prevention and Treatment of Gastrointestinal Malignancies, 9-12 Jan 1995, Köln, Germany (abstract 37).
11. Saltz LB, Kanowitz J, Kemeny NE, et al. A phase I clinical and pharmacokinetic study of irinotecan (CPT-11), 5-fluorouracil and leucovonin in patients with advanced solid tumours. J Clin Oncol. in press.
12. Saltz L. Irinotecan (CPT-11) in combination chemotherapy regimens. Cancer Invest 1996, 14 (Suppl. 1), p. 38 (abstract).
13. Grossin F, Barbault H, Benhammouda A, et al. A phase I pharmacokinetics study of concomitant CPT-11 (C) and 5FU (F) combination. Annual Meeting of the American Association for Cancer Research (AACR), 23 April 1996, Washington (abstract).
14. Shimada Y, Sasaki Y, Sugano K, et al. Combination phase I study of CPT-11 (irinotecan) combined with continuous infusion of 5-fluorouracil (5FU) in metastatic colorectal cancer. Proc Am Soc Clin Oncol 1993, 12, 196 (abstract 575).
15. Saltz L, Kanowitz J, Kemeny N, et al. Phase I trial of irinotecan (CPT-11), 5-fluorouracil (FU) and leucovorin (LV) in patients with advanced solid tumors. Proc Am Soc Clin Oncol 1995, 14, 476 (abstract 1546).
16. Liu LF. Biochemistry of camptothecins. In Potmesil M. ed Camptothecins: New Anticancer Agents. Boca Raton, Florida, CRC Press, 1985, 9-19.
17. Verweij J, Schellens JH. Topoisomerase I inhibition: a new target or new missiles? Ann Oncol 1995, 6, 102-104.
18. Slichenmyer WJ, Rowinsky EK, Donehower RC, Kaufmann SH. The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 1993, 85, 271-291.
19. Giovanella BC, Stehlin JS, Wall ME, et al. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 1989, 246, 1046-1048.
20. Burris III HA, Fields SM. Topoisomerase I inhibitors. An overview of the camptothecin analogs. Hematol Oncol Clin North Am 1994, 8, 333-355.
21. Savaraj N, Xu R, Wu CJ, et al. Correlation of in-vitro antitumor activity of irinotecan and topoisomerase I activity and levels in brain tumor. Proc Am Soc Clin Oncol 1995, 143, 492 (abstract 1610).
22. Creemers GJ, Lund B, Verweij J. Topoisomerase I inhibitors: topotecan and irinotecan. Cancer Treat Rev 1994, 20, 73-96.
23. Kunimoto T, Nitta K, Tanaka T, et al. Antitumor activity of 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin, a water-soluble derivative of camptothecin, against murine tumors. Cancer Res 1987, 47, 5944-5947.
24. Tsuruo T, Matsuzaki T, Matsushita M, Saito H, Yokokura T. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother Pharmacol 1988, 21, 71-74.
25. ®. Drugs Future 1993, 18, 273-277.